A double-blind, parallel, placebo-controlled, randomized study to evaluate the efficacy and safety of 3 different oral dose levels (1, 2, and 4 mg) of CCI-779 [temsirolimus[ in subjects with active rheumatoid arthritis on concomitant methotrexate therapy

Trial Profile

A double-blind, parallel, placebo-controlled, randomized study to evaluate the efficacy and safety of 3 different oral dose levels (1, 2, and 4 mg) of CCI-779 [temsirolimus[ in subjects with active rheumatoid arthritis on concomitant methotrexate therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 12 Feb 2013 Additional lead trial entre added as reported by ClinicalTrials.gov record.
    • 21 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top